Clinical applications of mesenchymal stem cells

被引:0
作者
Shihua Wang
Xuebin Qu
Robert Chunhua Zhao
机构
[1] Chinese Academy of Medical Sciences & Peking Union Medical College,Institute of Basic Medical Sciences & School of Basic Medicine, Center of Excellence in Tissue Engineering
来源
Journal of Hematology & Oncology | / 5卷
关键词
Mesenchymal Stem Cell; Primary Biliary Cirrhosis; Immunomodulatory Function; Mesenchymal Stem Cell Transplantation; Allogeneic MSCs;
D O I
暂无
中图分类号
学科分类号
摘要
Mesenchymal stem cells (MSC) have generated a great amount of enthusiasm over the past decade as a novel therapeutic paradigm for a variety of diseases. Currently, MSC based clinical trials have been conducted for at least 12 kinds of pathological conditions, with many completed trials demonstrating the safety and efficacy. This review provides an overview of the recent clinical findings related to MSC therapeutic effects. Roles of MSCs in clinical trials conducted to treat graft-versus-host-disease (GVHD) and cardiovascular diseases are highlighted. Clinical application of MSC are mainly attributed to their important four biological properties- the ability to home to sites of inflammation following tissue injury when injected intravenously; to differentiate into various cell types; to secrete multiple bioactive molecules capable of stimulating recovery of injured cells and inhibiting inflammation and to perform immunomodulatory functions. Here, we will discuss these four properties. Moreover, the issues surrounding clinical grade MSCs and principles for MSC therapeutic approaches are also addressed on the transition of MSCs therapy from bench side to bedside.
引用
收藏
相关论文
共 521 条
  • [1] Friedenstein AJ(1968)Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues Transplantation 6 230-247
  • [2] Petrakova KV(2004)Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta Stem Cells 22 1338-1345
  • [3] Kurolesova AI(2006)Minimal criteria for defining multipotent mesenchymal stromal cells The International Society for Cellular Therapy position statement. Cytotherapy 8 315-317
  • [4] Frolova GP(1995)Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use Bone Marrow Transplant 16 557-564
  • [5] In 't Anker PS(2011)Mesenchymal stem cells: from experiment to clinic Fibrogenesis Tissue Repair 4 20-70
  • [6] Scherjon SA(2008)Prevention and treatment of acute GvHD Bone Marrow Transplant 41 S65-1441
  • [7] Kleijburg-van Dder Keur C(2010)HLA-matched sibling transplantation with G-CSF mobilized PBSCs and BM decreases GVHD in adult patients with severe aplastic anemia J Hematol Oncol 3 51-1397
  • [8] de Groot-Swings GM(2008)Current status of haploidentical stem cell transplantation for leukemia J Hematol Oncol 1 27-3362
  • [9] Claas FH(2004)Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells Lancet 363 1439-1586
  • [10] Fibbe WE(2006)Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease Transplantation 81 1390-32